Get the Stockscreener App
0.7399
6.06%
0.0423
After Hours:
.73
-0.0099
-1.34%
Longeveron Inc stock is traded at $0.7399, with a volume of 297.65K.
It is up +6.06% in the last 24 hours and up +18.90% over the past month.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
See More
Previous Close:
$0.6976
Open:
$0.7021
24h Volume:
297.65K
Relative Volume:
0.89
Market Cap:
$23.38M
Revenue:
$1.22M
Net Income/Loss:
$-22.43M
P/E Ratio:
-0.6398
EPS:
-1.1564
Net Cash Flow:
$-18.78M
1W Performance:
-3.41%
1M Performance:
+18.90%
6M Performance:
+38.09%
1Y Performance:
-2.03%
1-Day Range:
$0.7002
$0.7549
1-Week Range:
$0.67
$0.7978
52-Week Range:
$0.475
$1.23
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.7399 | 23.60M | 1.22M | -22.43M | -18.78M | -1.1564 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
Longeveron Stock Price Forecast. Should You Buy LGVN? - StockInvest.us
Longeveron Inc. (LGVN) investors disclose 9% beneficial stake through warrant holdings - Stock Titan
Longeveron LLC earnings missed by $0.01, revenue fell short of estimates - Investing.com Nigeria
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update - BioSpace
Longeveron Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Longeveron Q2 Results: Net loss rises 22% to $6.1 million - scanx.trade
LGVN: Q2 2026 net loss rose to $6.1M as HLHS trial data and XPRIZE finalist status drive near-term focus - TradingView
Earnings call transcript: Longeveron misses Q2 2026 estimates as cash runs tight - Investing.com
Longeveron Inc. (LGVN) Q2 FY2026 earnings call transcript - Yahoo Finance
Longeveron Reports $6.1 Million Q2 Net Loss Ahead Of ELPIS II Data - Quiver Quantitative
Longeveron Q2 net loss widens on higher legal, clinical trial costs - TradingView
LGVN: Q2 2026 net loss rose 22% as clinical and legal expenses increased ahead of key trial results - TradingView
Longeveron Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design - Stocktwits
Earnings To Watch: Longeveron Inc (LGVN) Q2 2026 -- GF Value Sees 58% Downside - Yahoo Finance
Longeveron Selected as XPRIZE Healthspan Milestone 2 Awardee for Laromestrocel Clinical Trial Results - Quiver Quantitative
Longeveron Named a Finalist Team and Will Receive a - GlobeNewswire
Longeveron Inc. (LGVN): Millennium group discloses 5.2% Class A equity stake - Stock Titan
Longeveron Restores Nasdaq Compliance with New Audit Committee - TipRanks
Earnings Preview: Longeveron to Report Financial Results Post-market on August 12 - Moomoo
LGVN Q2'26 Earnings: revenue estimate is 326.00K USD - TradingView
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming DeadlineLGVN - TMX Newsfile
Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026 - The Manila Times
Longeveron will share second-quarter results after markets close Aug. 12 - Stock Titan
Longeveron (LGVN) Surges 13.45% to $0.68: Clinical-Stage Biotech Tests Key ResistanceAdvance Decline Volume - dars.gov.et
Longeveron Inc. Announces Reconstitution of Audit Committee - marketscreener.com
Longeveron Inc. Revenue Breakdown – NASDAQ:LGVN - tradingview.com
Longeveron Inc (LGVN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Longeveron Inc (LGVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Longeveron Inc (LGVN) Cash Flow - TradingKey
Longeveron Inc (LGVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LGVN|Longeveron Inc|Price:0.600|Chg%:-0.007 - TradingKey
Longeveron Inc (LGVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Longeveron Inc (LGVN) Institutional Confidence - TradingKey
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
TradingKey - TradingKey
Longeveron Inc (LGVN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors - BioSpace
Longeveron Inc. Elects Deborah D. Ascheim, M.D., to Board of Directors - Quiver Quantitative
Longeveron : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
$Longeveron (LGVN.US)$ - moomoo.com
Longeveron Enhances CEO Compensation and Retention Protections - TipRanks
Can Upcoming HLHS Trial Data Drive A Valuation Re-Rating For Longeveron? - RTTNews
Longeveron Inc. (LGVN) Q1 2026 Earnings: EPS Misses Estimates, Stock Declines 3.45%New Analyst Coverage - dars.gov.et
Longeveron Inc. Signs Revised CEO Employment Agreement – Key Details from July 2026 Form 8-K Filing - Minichart
Longeveron Inc. (LGVN) director files Form 3 showing no share holdings - Stock Titan
Longeveron (NASDAQ: LGVN) updates CEO severance and equity vesting - Stock Titan
Longeveron Inc. (LGVN) director Leah Cann reports no stock ownership - Stock Titan
Longeveron Presents AAIC Data Showing Laromestrocel Stabilizes Brain Inflammation in Alzheimer’s Disease - Quiver Quantitative
Stem cell therapy laromestrocel links brain scan changes to better cognition in Alzheimer’s trial - Stock Titan
Longeveron therapy reduces neuroinflammation in Alzheimer’s patients - scanx.trade
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):